Streetbeat News

Analyst Ratings

FMC

RBC Capital analyst Arun Viswanathan maintains an Outperform rating on FMC Corporation (NYSE:FMC) but lowers the price target from $61 to $59.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 3:12 pm

AAPL

GOOGL

META

MSFT

NVDA

QQQ

SPY

TSLA

The Market Clubhouse Morning Memo for February 8th, 2024, provides a trade strategy for SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA, based on a proprietary formula considering price, volume, and options flow. It offers detailed analysis for each asset, suggesting potential breakouts or reversals. The memo also highlights the importance of today's trading session due to the release of employment figures, wholesale data, Treasury's Bill Auction, and a speech by FOMC member Thomas Barkin.

Portfolio Pulse from RIPS

February 08, 2024 | 3:11 pm

ESS

RBC Capital analyst Brad Heffern maintains an Outperform rating on Essex Property Trust (NYSE:ESS) and raises the price target from $237 to $239.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 3:10 pm

EMR

RBC Capital analyst Deane Dray maintains an Outperform rating on Emerson Electric (NYSE:EMR) and raises the price target from $106 to $120.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 3:03 pm

NEM

Analyst ratings for Newmont (NYSE:NEM) show a mix of opinions, with recent actions including downgrades and new price targets. The average 12-month price target is now $46.00, down from $49.67. Newmont, the world's largest gold miner, has seen a revenue decline of -5.35% in the last quarter but maintains strong profitability indicators such as net margin and ROE. The company's debt-to-equity ratio is higher than the industry average, indicating financial risk.

Portfolio Pulse from Benzinga Insights

February 08, 2024 | 3:00 pm

CVS

Recent analyst ratings for CVS Health (NYSE:CVS) show a mix of bullish and somewhat bullish perspectives, with a slight decrease in the average 12-month price target to $91.00 from $94.00. The company's financial performance is strong, with significant revenue growth, high net margin, and effective debt management. CVS Health's diverse healthcare services and recent acquisition of Oak Street highlight its strategic expansion.

Portfolio Pulse from Benzinga Insights

February 08, 2024 | 3:00 pm

CRC

California Resources (NYSE:CRC) received mixed analyst ratings in the latest quarter, with a shift towards a more bullish outlook. The average 12-month price target was adjusted to $63.6, down from $65.33, reflecting a 2.65% decline. Analysts' actions varied, with some raising and others lowering their price targets. The company, an independent oil and natural gas producer in California, faces challenges such as a -24.72% revenue decline and below-industry benchmarks in financial health indicators.

Portfolio Pulse from Benzinga Insights

February 08, 2024 | 3:00 pm

CCK

RBC Capital analyst Arun Viswanathan maintains an Outperform rating on Crown Holdings (NYSE:CCK) but lowers the price target from $110 to $97.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 2:58 pm

CFLT

RBC Capital analyst Matthew Hedberg has maintained an Outperform rating on Confluent (NASDAQ:CFLT) and increased the price target from $30 to $35.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 2:56 pm

CRC

RBC Capital analyst Scott Hanold has maintained an Outperform rating on California Resources (NYSE:CRC) and increased the price target from $65 to $70.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 2:54 pm